Lancet Infectious Diseases

Article	Citations
Transaminases and serum albumin as early predictors of severe dengue – Authors' reply	1743
Environment and infectious diseases	1289
A step forward in the journey towards hookworm vaccines	928
Listeria monocytogenes: a rare, deadly cause of peritonitis	678
Surge of cutaneous leishmaniasis in Pakistan	601
Is ceftriaxone similarly effective to benzylpenicillin in neurosyphilis? – Authors' reply	598
Research in brief	594
Research in brief	491
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting	402
Attention to skin-related neglected tropical diseases	379
Infectious disease surveillance update	376
Chronicling PEPFAR's work in Africa	357
Ordinary people in extraordinary times	325
Infectious disease surveillance update	302
Promoting diversity and equity in publishing	289
Entering a labyrinth of COVID-19 stories	287
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7	279
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria	279
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations	270
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect	261
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study	260
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges	248
Adaora “Ada” Alise Adimora	247
The superiority of bivalent over monovalent booster vaccines	242
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum	236

DNDi receives Dutch funding boost	235
COVID-19 vaccination protects children and adolescents	227
Can the USA return to pre-COVID-19 normal by July 4?	225
Reflecting on lessons from the 2014–16 Ebola virus outbreak	223
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis	217
Bold measures to accelerate malaria elimination	214
A patient with secondary syphilis following incomplete treatment of primary infection	208
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations	207
HIV vaccine trial failure	205
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco	204
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden	191
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial	191
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study	186
Threat of HIV and tuberculosis drug resistance after US funding cuts	184
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C	172
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial	171
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial	171
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines	168
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis	167
Updated criteria for paediatric sepsis and septic shock	166
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic	166
The interplay between COVID-19 restrictions and vaccination	166
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review	163
Transitioning to endemicity with COVID-19 research	160
The next chapter for Africa's genomic initiatives	159
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom	157
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1	157
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study	156
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study	156
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blin	156
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial	154
Measles immunity gaps and outbreak risk in a shifting landscape	152
Mpox in people with past infection or a complete vaccination course: a global case series	150
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation	150
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study	150
The importance of understanding the infectious microenvironment	148
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2	147
Supporting healthcare access for refugees and migrants	146
History and evolution of tuberculosis and global health	145
Assessment of experimental malaria vaccine induced protection in pre-exposed populations	143
Election of Regional Director for the Western Pacific	142
Severe influenza: is there a role for antiviral combinations?	140
The implications of mpox breakthrough infections on future vaccination strategies	140
Sizing the reservoirs of malaria transmission: the contribution of school-aged children	135
Correction to Lancet Infect Dis 2021; 21: 962–74	135
Emil Gotschlich	133
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world	131
Interplay of infection and vaccination in long-term protection from COVID-19	131
Immune evasiveness of SARS-CoV-2 variants and vaccine selection	130
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis	129

Global cholera resurgence—a preventable tragedy	129
Super-spreaders: a historical review	128
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant	127
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis	125
Elisabeth Presterl—always looking forward	124
WHO Pathogen X conference	123
Addressing the shortage of cholera vaccines	122
WHO's first global infection prevention and control report	122
Malaria vaccine development in Mali: a step towards transmission-blocking strategies	118
Allergic bronchopulmonary aspergillosis with chest pain as atypical symptoms	118
Correction to Lancet Infect Dis 2023; 23: e469	117
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5	117
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-0	116
Correction to Lancet Infect Dis 2021; 21: 629–36	116
Research in brief	115
Full-dose NSAIDs at the first sign of respiratory infection?	113
Theresa Ochoa—staying on top of infectious diseases in Peru	111
Infectious disease surveillance update	110
Is combination antiviral therapy for influenza the optimal approach?	108
Curing chronic hepatitis B virus infection	102
Tuberculosis recovery in Georgia: implementing more by 24	102
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86	101
Vaccine and surveillance implications of dengue underdetection	101
The response of mpox-associated inflammatory syndrome to steroid therapy	101
Research in brief	101
RSV prevention: public health lessons from the southern hemisphere	98
Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation	97
Correction to Lancet Infect Dis 2025; 25: e47–58	97
Guidelines adherence as a major protective aspect to increase survival rate in patients with candidaemia in Europe	95
New flavours of tuberculosis treatment for children	95
Serpiginous-like choroiditis in ocular tuberculosis	94
Research in brief	94
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products—an update	93
We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site	92
Worrying lack of funding for tuberculosis	91
Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention	91
Post-viral sequelae of COVID-19 and influenza	91
Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance	90
COVID-19 mortality in Africa and Asia – Authors' reply	90
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study	90
High-dose primaquine reduces vivax relapses: time for change	89
The global burden of cryptococcosis—a neglected tropical disease?	88
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	88
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia	87
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?	86
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	86
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa	86
Twin threats: climate change and zoonoses	85
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	85
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study	84
Effect of change in vaccine schedule on pertussis epidemiology in France: a modelling and serological study	84
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis	84
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study	83
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents	82
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-	82
Vaccine pragmatism in the 21st century	81
Statistical concerns for meta-analysis of rare events and small sample sizes – Authors' reply	81
Amal Saif Al-Maani—fighting antimicrobial resistance	80
A step closer to elimination of meningococcal disease	79
Next-generation malaria subunit vaccines to reduce disease burden in African children	79
Infectious disease surveillance update	79
Correction to Lancet Infect Dis 2021; 21: 929–38	79
Spreading awareness on lymphatic filariasis	78
A tale of potential mpox reinfection	77
Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7	77
Child-friendly rifapentine formulation is a game changer	77
Incidence and risk factors of tuberculosis among 420 854 household contacts of patients with tuberculosis in the 100 Million Brazilian Cohort (2004–18): a cohort study	75
Effectiveness of pyriproxyfen-pyrethroid and chlorfenapyr-pyrethroid long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs for malaria control in the third year post-distribution:	75
Gender and geographical representation at infectious diseases and clinical microbiology conferences	75
COVID-19 mortality in Africa and Asia	75
The spatiotemporal ecology of Oropouche virus across Latin America: a multidisciplinary, laboratory-based, modelling study	74
Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study	73
DoxyPEP: thinking towards implementation	73
Highlights from ECCMID 2022	71
Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south	71
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial	71
Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	71
Clindamycin-resistant Streptococcus pyogenes in Chinese children	71
Ivermectin for malaria control in mass drug administration programmes	71
Correction to Lancet Infect Dis 2023; published online Aug 3. https://doi.org/10.1016/S1473-3099(23)00344-4	70

Correction to Lancet Infect Dis 2023; 23: e259–65	70
Pui-Ying Iroh Tam	69
Sir Michael Anthony Epstein	69
Is the end of gonorrhoea in sight?	69
Research in brief	69
On the frontline during the COVID-19 pandemic	69
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil	68
Sleeping sickness: time for dreaming	68
Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch	68
Moxidectin versus ivermectin for strongyloidiasis control	68
Social workers and neglected tropical diseases	67
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices	67
Prevention of non-ventilator-associated hospital-acquired pneumonia in Switzerland: a type 2 hybrid effectiveness–implementation trial	67
Human ocular thelaziosis—a zoonosis of the eye	66
doxyPEP: a controversial new tool against STIs	66
Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials	66
Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa	66
Imprinted hybrid immunity against XBB reinfection	65
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial	65
Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluste	65
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster	64
Re-emergence of Oropouche virus in Brazil and Latin America	64
Advancing integration: progress reported for skin NTDs	64
Outbreaks compound Brazil's flooding disaster	64
Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows	64
RH5.1/Matrix-M: highlighting blood-stage malaria vaccines	64
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis	64
Lessons learnt from conducting a randomised clinical trial in eumycetoma	64
National case series of group A streptococcus pleural empyema in children: clinical and microbiological features	63
A rare case of rabies-like Australian bat lyssavirus infection	62
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study	61
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study	61
The origin of SARS-CoV-2 variants of concern	61
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3	61
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial	61
The urgent need to scale-up fungal diagnostics in Africa	60
Lassa fever research priorities: towards effective medical countermeasures by the end of the decade	60
Lien Jih-ching	60
Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study	60
Experts react to SAGO's preliminary report	60
Hong Kong's fifth COVID-19 wave—the worst yet	60
Detective doctor decodes AIDS mystery	59
Correction to Lancet Infect Dis 2023; 23: 789	59
Monkeypox trial to begin in DR Congo	59
Infectious disease surveillance update	59
Antibody durability at 1 year after Sputnik V vaccination	58
Randomised controlled trials for mpox in endemic countries	57
Antibiotic stewardship in the real world	57
Zika vaccines: can we solve one problem without creating another one?	57
Alexandra King—promoting Indigenous self-determination	56
A vanquished threat or a cautionary tale?	56
Correction to Lancet Infect Dis 2025; 25: e11–12	55
Understanding the immunogenicity of RTS,S in infants	55
Developing the EAVE III platform for future health crises	55
Humanitarian crisis in Tigray amidst civil war	54
Correction to Lancet Infect Dis 2022; published online Jan 25. https://doi.org/10.1016/S1473-3099(21)00586-7	54
Transmissibility of SARS-CoV-2 among fully vaccinated individuals	54
The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus	54
A step forward for Plasmodium falciparum malaria transmission-blocking vaccines	54
Hospital admissions for group A streptococcal infections in England: current rates and historical perspective	53
A new formulation of praziquantel to achieve schistosomiasis elimination	53
Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021–22: a descriptive epidemiological study	53
Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis	52
Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions	52
Deaths of unknown cause in DR Congo	52
Learning and confirming in publicly funded antiviral trials	52
Global measles cases up 20% in 2023	51
Mpox control strategies: using behaviour change to complement, not replace, vaccination	51
Correction to Lancet Infect Dis 2025; published online Feb 13. https://doi.org/10.1016/S1473-3099(24)00749-7	51
A shared history	50
Understanding vancomycin nephrotoxicity augmented by β-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and β-lactam chemistry	50
Salmonella Typhimurium outbreak linked to chocolate	50
Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia	50
H5N1 avian influenza: tracking outbreaks with real-time epidemiological data	50
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomi	50
What chikungunya teaches us about COVID-19	49
Correction to Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S1473-3099(23)00731-4	48
Impact of COVID-19 on migrants and refugees	48
Artificial intelligence to transform public health in Africa	48
Struggling with a new dengue epidemic in Nepal	48
COVID-19 versus influenza: the need to align policies with COVID-19 realities	47
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African c	47
Revisiting oral antivirals for COVID-19 in the hospital setting	47
Successful use of interferon alfa-2a for persistent parvovirus B19 infection	47
Antiblackness in the Ebola response in Sierra Leone	47
Azithromycin mass drug administration: balancing survival benefits and risks in children	46
Reporting of deaths during cholera outbreaks: case fatality ratio and community deaths	46
Lessons from the English primary care sentinel network's response to the COVID-19 pandemic	46
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden	46
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study	45
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation	45
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-base	45
An imaginary pandemic and its consequences	45
WHO Health For All film awards 2022	45
A new key-player for onchocerciasis elimination	45